daily
Description
Alexion Pharmaceuticals, Inc. (Alexion), is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its marketed product Soliris (eculizumab) is the first and only therapeutic approved for patients with two ultra-rare and severe disorders resulting from chronic uncontrolled activation of the complement component of the immune system: paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare and life-threatening blood disorder, and atypical hemolytic uremic syndrome (aHUS), an ultra-rare and life-threatening genetic disease. The Company is also evaluating other indications for Soliris in other diseases in which chronic uncontrolled complement activation is the underlying mechanism, and it is progressing with other biotechnology product candidates in ultra-rare and severe disorders, which are in various stages of development.
Address
352 Knotter Dr
CHESHIRE, CT 06410-1138
United States
CHESHIRE, CT 06410-1138
United States
Website
http://www.alxn.com/Key stats and ratios
| Q4 (Dec '14) | 2014 | |
| Net profit margin | 25.58% | 29.41% |
| Operating margin | 33.98% | 38.89% |
| EBITD margin | - | 43.10% |
| Return on average assets | 15.20% | 17.47% |
| Return on average equity | 19.14% | 23.11% |
| Employees | 2,273 |
weekly
monthly
No comments:
Post a Comment